Evidence map›Paper›PMID 27722696›Full record

ArticleOrganic & biomolecular chemistry2016

Access to site-specific Fc-cRGD peptide conjugates through streamlined expressed protein ligation.

S Frutos, J B Jordan, M M Bio, T W Muir, O R Thiel, M Vila-Perelló

Open access · greenAbstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

S FrutosProteoDesign S.L., Baldiri Reixac 10-12, 08028 Barcelona, Spain. miquel.vila@proteodesign.es.
J B JordanAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. othiel@amgen.com.
M M BioAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. othiel@amgen.com.
T W MuirDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA.
O R ThielAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. othiel@amgen.com.
M Vila-PerellóProteoDesign S.L., Baldiri Reixac 10-12, 08028 Barcelona, Spain. miquel.vila@proteodesign.es.ORCID http://orcid.org/0000-0001-7554-4895
Amgen (United States) · USFC Barcelona · ESPrinceton University · US

Funding

Structure, Function and Applications of InteinsR37GM086868 · NIGMS · PRINCETON UNIVERSITY · PI MUIR, TOM · 2012 to 2021
$5.4M
NIGMS NIH HHS R37 GM086868
6 · The paper itself

Abstract

An ideal drug should be highly effective, non-toxic and be delivered by a convenient and painless single dose. We are still far from such optimal treatment but peptides, with their high target selectivity and low toxicity profiles, provide a very attractive platform from which to strive towards it. One of the major limitations of peptide drugs is their high clearance rates, which limit dosage regimen options. Conjugation to antibody Fc domains is a viable strategy to improve peptide stability by increasing their hydrodynamic radius and hijacking the Fc recycling pathway. We report the use of a split-intein based semi-synthetic approach to site-specifically conjugate a synthetic integrin binding peptide to an Fc domain. The strategy described here allows conjugating synthetic peptides to Fc domains, which is not possible via genetic methods, fully maintaining the ability of both the Fc domain and the bioactive peptide to interact with their binding partners.

Indexed as

Amino Acid SequenceBinding SitesHumansHydrolysisImmunoglobulin Fc FragmentsIntegrin alphaVbeta3Peptides, Cycliccyclic arginine-glycine-aspartic acid peptideImmunoglobulin Fc FragmentsIntegrin alphaVbeta3Peptides, Cyclic

Identifiers

PMID27722696
PMCPMC5978688
OpenAlexW2523040272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.